Manipal Health Enterprises IPO: Price Band, Lot Size, Financials, Valuation and RHP Review

India’s largest hospital network by bed capacity is finally coming to market. Manipal Health Enterprises is raising about ₹9,275 crore — ₹8,000 crore of fresh capital and a comparatively small ₹1,275 crore sell-down — at ₹560–590 a share. Bidding runs 29–31 July 2026, with listing on BSE and NSE pencilled in for 5 August.

The split is unusual for a mainboard issue: because the company doesn’t meet the net tangible asset test under Regulation 6(1)(a), the offer is being made under Regulation 6(2) — which means at least 75% of the net offer must go to QIBs and retail gets no more than 10%. Retail applicants will be competing for a thin slice. At the top of the band, one lot of 25 shares costs ₹14,750.

Manipal Health Enterprises runs a pan-India network of multispecialty hospitals under the Manipal Hospitals brand, from routine outpatient work through to complex tertiary and quaternary interventions. As of 31 March 2026 that network stood at 49 hospitals and 13,037 licensed beds across 14 states and union territories — the largest pan-India multispecialty network by bed capacity and the second largest by hospital count, per the CRISIL report commissioned for the offer. It served 7.63 million patients in FY2026 and had 11,064 doctors available across its hospitals.

The company is the only private chain leading three metro markets at once — Bengaluru, Kolkata and Pune — which between them account for 5,376 licensed beds. It keeps a deliberate balance between big cities and smaller ones: 46.78% of licensed beds sit in metros, 53.22% outside them. The lineage runs back to the Pai family and Kasturba Medical College in Manipal; the flagship Old Airport Road hospital in Bengaluru has been rated the city’s number one for 20 straight years by The Week–Hansa survey, and 41 of the 49 hospitals carry NABH accreditation.

Karnataka still supplies close to half of FY2026’s ₹10,335.75 crore revenue, though the concentration has been falling fast — it was 59.98% two years earlier. Eastern India (West Bengal, Odisha, Jharkhand, Sikkim) has been the big mover, climbing from 11.14% to 22.42% on the back of the AMRI and Medica acquisitions. On a pro forma basis giving full-year effect to Sahyadri, Maharashtra and Goa would be 16.38% rather than 11.52%. Figures are drawn from the company’s RHP dated 23 July 2026.

By specialty, the high-acuity CONGO-R group — cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences — contributed 64.30% of gross inpatient revenue in FY2026, up from 61.55% in FY2024. By payor, insurance and third-party administrators are the biggest single source at 49.68%, with cash patients at 30.33% and government schemes 13.80%.

The two named objects account for roughly ₹6,127 crore — about 77% of the fresh issue. The larger slice redeems non-convertible debentures issued by subsidiary Manipal Hospitals Private Limited to fund the Sahyadri purchase; those NCDs carry a mandatory prepayment clause triggered by listing, and a 9.03% coupon. That single repayment covers 47.47% of the group’s total consolidated borrowings of ₹11,185.02 crore as of 31 May 2026. The smaller slice buys out the final 9.84% tranche of Sahyadri Hospitals from Summit Bidco.

The line that changes the shape of this business is borrowings: they more than doubled in FY2026, from ₹4,766.83 crore to ₹10,553.43 crore, and leverage went from a comfortable 2.0x adjusted EBITDA to 3.74x. That is exactly what the fresh issue is designed to reverse. Cash generation, meanwhile, held up well — operating cash flow rose 32% to ₹2,078.40 crore, and the company ran a negative working capital cycle of 13 days.

Revenue per occupied bed rose 8.9% in FY2026 while average length of stay fell again — a good combination, and evidence the shift toward complex specialties is translating into pricing rather than just longer admissions. Occupancy dipping to 64.47% is the counterweight, and it is largely a function of absorbing Sahyadri’s 1,606 beds mid-year. Only 6,227 of 13,037 licensed beds were operational on average in FY2026, so there is real headroom — and real ramp-up risk. The company plans roughly 483 more beds at existing hospitals and about 1,943 greenfield beds by 2030.

Kangto, Imperius and Kabru are all indirect wholly owned subsidiaries of Temasek Holdings, which is why the Singapore names dominate the register. Worth noting for context: the weighted average cost of all shares transacted in the last twelve months was ₹580.41 — effectively at the price band — against ₹72.04 over three years. Seven shareholders are selling in the OFS, led by Imperius (up to 1,08,08,861 shares) and Manipal Education and Medical Group India (up to 67,92,002 shares).

The three peers named in the RHP — Apollo Hospitals, Fortis Healthcare and Max Healthcare — traded at 66.15x, 70.22x and 74.55x respectively as of 21 July 2026, averaging 70.31x. So at the cap Manipal is asking for a premium to every one of them on trailing earnings, even before adjusting for the post-issue share count. The bull case is that FY2026 earnings are artificially depressed by acquisition-related finance costs that the fresh issue is about to remove — roughly ₹5,553 crore of 9.03% debt going away should feed straight back into the bottom line. The bear case is that you are paying a premium multiple on already-optimistic numbers, with occupancy at a three-year low and integration still unproven. This one hinges more than most on whether you underwrite next year’s earnings rather than last year’s.

Anchor bidding opens on Tuesday, 28 July 2026 — one working day before the public issue. Under SEBI ICDR rules the company may allocate up to 60% of the QIB portion to anchor investors on a discretionary basis, of which 40% is reserved for domestic institutions: 33.33% for mutual funds and 6.67% for life insurance companies and pension funds. Given the size of the raise and the roster of seven bookrunners, this is the number most worth watching before the issue opens — a well-subscribed anchor book with real domestic mutual fund participation would say a lot about institutional appetite at a 70-plus multiple. We will update this section once the allocation is disclosed.